These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. dell'Aquila C; Zoccolella S; Cardinali V; de Mari M; Iliceto G; Tartaglione B; Lamberti P; Logroscino G Parkinsonism Relat Disord; 2013 Nov; 19(11):980-5. PubMed ID: 23968651 [TBL] [Abstract][Full Text] [Related]
28. Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy. Chen MJ; Lu JY; Li XY; Jiao FY; Zuo CT; Wang J; Liu FT; Yang YJ Front Aging Neurosci; 2022; 14():998255. PubMed ID: 36092815 [TBL] [Abstract][Full Text] [Related]
29. Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. Hall DA; Stebbins GT; Litvan I; Bordelon Y; Riley DE; Leverenz J; Standaert DG Mov Disord Clin Pract; 2016; 3(1):65-67. PubMed ID: 30363575 [TBL] [Abstract][Full Text] [Related]
30. Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. Krismer F; Seppi K; Wenning GK; Abler V; Papapetropoulos S; Poewe W Mov Disord; 2016 Oct; 31(10):1577-1581. PubMed ID: 27474888 [TBL] [Abstract][Full Text] [Related]
31. A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy. Ghosh BC; Carpenter RH; Rowe JB PLoS One; 2013; 8(9):e74486. PubMed ID: 24058574 [TBL] [Abstract][Full Text] [Related]